Compare CRWS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | ANTX |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 31.2M |
| IPO Year | 1994 | 2022 |
| Metric | CRWS | ANTX |
|---|---|---|
| Price | $2.91 | $1.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 44.3K | ★ 72.7K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.96% | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $1.00 |
| 52 Week High | $4.09 | $1.49 |
| Indicator | CRWS | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 50.72 |
| Support Level | $2.81 | $1.02 |
| Resistance Level | $2.94 | $1.16 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.79 | 70.00 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.